Indexing in SciSearch means that articles published in the journal are systematically cataloged, with structured metadata including author names, affiliations, abstracts, and cited references. This infrastructure allows the journal’s output to be discovered through standardized searches, tracked for citation activity, and aggregated into bibliometric analyses. For authors, inclusion in the database ensures that their work is counted in institutional assessments and that citations to their papers are captured in the citation indexes that underpin modern research evaluation.

Alongside the indexing achievement, the journal recorded an Impact Factor of 5.5 in 2022, according to the source announcement. Within the Journal Citation Reports category of Pharmacology and Pharmacy, that figure corresponded to a Q1 quartile ranking, placing the journal 48th out of 278 titles in the category. Quartile rankings divide journals in a category into four groups by citation performance, and Q1 designates the top quarter, a status widely regarded as an indicator of strong relative influence within a field.

The Impact Factor itself is calculated from citations accrued in a given year to items published in the two preceding years, divided by the number of citable items published in that window. A score of 5.5 indicates that, on average, recent articles in the journal were cited more than five times within the measurement period. While bibliometricians caution that the metric reflects aggregate citation behavior rather than the quality of any individual paper, it remains one of the most consulted indicators when researchers choose where to submit manuscripts and when libraries decide which subscriptions to maintain.

For a journal focused on pharmaceutical investigation, the Q1 position in Pharmacology and Pharmacy carries particular weight. The category is crowded and competitive, spanning basic pharmacology, clinical pharmacy practice, drug delivery science, and regulatory science. Ranking 48th of 278 means the journal sits comfortably within the upper tier of a broad and active field, competing for attention with long-established titles that have decades of accumulated citation history.

The timing of the SciSearch indexing in 2021 is significant for the journal’s trajectory. Journals typically need a period of consistent publication and editorial rigor before they are evaluated for Web of Science coverage, and newly indexed titles generally receive their first Impact Factor only after a full citation window has elapsed. The 2022 Impact Factor therefore represents an early but meaningful validation of the journal’s growing footprint in the pharmaceutical sciences literature.

From the perspective of the research community, expanded indexing and strong citation metrics have practical consequences. Manuscript submissions tend to rise as visibility increases, which in turn allows editorial teams to be more selective. Authors in drug delivery, pharmacokinetics, and pharmaceutical formulation often weigh indexing status heavily because funding agencies and promotion committees in many countries explicitly require publications in Web of Science–indexed journals. The journal’s inclusion removes a barrier for authors in those systems and broadens its potential contributor base across Asia, Europe, and the Americas.

Librarians and information scientists also benefit from the development. Abstracting and indexing services create the connective tissue of scholarly communication: without them, discovering relevant articles across thousands of journals would be impractical. Coverage in SciSearch ensures that the journal’s content is integrated into discovery platforms used by universities and industry research groups, supporting systematic reviews, competitor intelligence in pharmaceutical R&D, and citation network analyses that map emerging research fronts in drug development.

The announcement, published through Springer’s journal updates for the Journal of Pharmaceutical Investigation, highlights how indexing and citation performance function as complementary signals. Indexing establishes that a journal meets baseline editorial and technical standards, while the Impact Factor and quartile ranking describe how its published work resonates with the research community. Together, they offer a concise summary of the journal’s standing: a title that has entered the mainstream of indexed pharmacology literature and, within two years, achieved a top-quartile citation profile in its category.

As the pharmaceutical sciences continue to expand, with growing attention to biologics, nanomedicine, and personalized drug delivery, the visibility provided by comprehensive indexing will shape which journals anchor the field’s scholarly record. For the Journal of Pharmaceutical Investigation, the 2021 SciSearch inclusion and the 2022 Impact Factor of 5.5, with its Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, mark a notable consolidation of its position among the publications that researchers in the discipline consult, cite, and trust.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, Web of Science, pharmaceutical sciences, journal citation metrics, Springer, scholarly publishing

Abstracting and indexing services form the backbone of modern scientific communication. When a journal is accepted into the Science Citation Index Expanded, it means that its published articles are systematically cataloged, metadata is extracted and standardized, and the content becomes discoverable through the Web of Science platform maintained by Clarivate. This process is far more than a bureaucratic formality. Inclusion in a major citation index determines whether researchers around the world can efficiently locate, retrieve, and cite a journal’s content. For pharmaceutical scientists, whose work often spans chemistry, pharmacology, formulation science, and clinical research, discoverability through trusted indexes is essential to ensuring that findings reach the practitioners and regulators who can act upon them.

The Science Citation Index Expanded, originally established as part of the Science Citation Index created by Eugene Garfield in the 1960s, has long served as one of the most selective and influential databases in academic publishing. Journals are admitted only after a rigorous evaluation process that examines editorial rigor, peer-review integrity, regularity of publication, international editorial diversity, and the citation behavior of the published literature. The fact that the Journal of Pharmaceutical Investigation entered SciSearch coverage in 2021 means that its articles published from that year onward are now tracked within the citation network that underpins modern bibliometrics, including the annual Journal Impact Factor calculations.

The Impact Factor itself remains the most widely recognized, and most widely debated, quantitative measure of a journal’s influence. Calculated each year by Clarivate, the metric reflects the average number of citations received in a given year by articles published in the journal during the two preceding years. An Impact Factor of 5.5 for 2022 indicates that, on average, articles published in the journal in 2020 and 2021 were cited 5.5 times in 2022 across the indexed literature. In the highly competitive Pharmacology and Pharmacy category, where hundreds of journals compete for the attention of a global research community, this average places the Journal of Pharmaceutical Investigation in the top tier of its discipline.

The quartile designation adds important context to the raw number. Ranking 48th among 278 journals in Pharmacology and Pharmacy corresponds to the Q1 band, the highest quartile of the category. Quartile rankings are derived by ordering all journals in a category by their Impact Factor and dividing the list into four equal groups. Q1 status is frequently used by research institutions, funding agencies, and university committees as a shorthand marker of journal prestige, influencing decisions about where researchers submit their work, how publications are weighted in hiring and promotion evaluations, and which journals libraries prioritize in their subscriptions. For authors weighing where to publish their pharmaceutical research, a Q1 designation with a 5.5 Impact Factor signals a venue with demonstrated reach and citation performance.

Pharmacology and pharmacy is one of the most densely populated categories in the Web of Science, reflecting the breadth of research that falls under its umbrella. The category encompasses basic pharmacological research into drug receptors and signaling pathways, medicinal chemistry and drug design, pharmacokinetics and drug metabolism, formulation and delivery technologies, clinical pharmacology, and pharmacy practice research. Journals in this space range from highly specialized outlets focused on narrow subfields to broad-spectrum publications that cover the full arc from molecule to medicine. Within this crowded landscape, achieving a position in the upper fifth of the category requires consistent publication of work that other researchers find useful enough to cite, year after year.

The Journal of Pharmaceutical Investigation has built its reputation on content that spans pharmaceutical technology, drug delivery systems, biopharmaceutics, and the clinical investigation of medicines. Its scope reflects the realities of contemporary drug development, where advances increasingly emerge at the boundaries between disciplines. Novel formulations such as lipid nanoparticles, long-acting injectables, and targeted delivery platforms demand expertise that bridges physical pharmacy, materials science, and regulatory science. Similarly, the evaluation of biosimilars, generics, and novel therapeutic modalities requires integration of analytical chemistry, pharmacokinetic modeling, and clinical trial methodology. A journal that serves as a conduit for this interdisciplinary work occupies a valuable position in the scientific ecosystem, and its citation performance suggests that the community recognizes that value.

Indexing in SciSearch also carries practical consequences for the researchers who publish in the journal. Articles included in the Science Citation Index Expanded are assigned digital object identifiers and standardized metadata that feed into institutional research information systems, national assessment exercises, and funder reporting requirements. In many countries, publication in indexed journals is a formal criterion for doctoral degree completion, grant eligibility, and academic advancement. For authors based in the Asia-Pacific region and beyond, where the Journal of Pharmaceutical Investigation has historically maintained strong connections through its publisher and editorial network, the journal’s expanded indexing profile enhances the portability and recognition of their published work across international evaluation systems.

The timing of the journal’s entry into the citation index is also noteworthy. Coverage beginning in 2021 means the journal’s recent publication record has been captured during a period of extraordinary activity in pharmaceutical research. The global pandemic accelerated investment in vaccine technology, antiviral therapeutics, and manufacturing science, while parallel advances in biologics, cell and gene therapies, and digital health technologies reshaped the drug development pipeline. Citation activity across pharmacology surged during this period, and journals positioned at the interface of pharmaceutical formulation and clinical investigation benefited from heightened attention to their subject matter. The 5.5 Impact Factor for 2022 reflects not only the journal’s editorial strategy but also the intensity of scientific exchange in its field during the measurement window.

Looking ahead, the combination of SciSearch indexing and Q1 standing positions the Journal of Pharmaceutical Investigation to attract submissions from a broader international author base and to deepen its role in shaping discourse on pharmaceutical innovation. Metrics are never a complete measure of a journal’s contribution, and the scholarly community continues to debate the appropriate weight given to Impact Factors in research assessment. Nevertheless, the journal’s current profile, indexed from 2021 with an Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, provides an objective snapshot of its standing. For a publication devoted to the investigation of medicines from laboratory bench to patient bedside, the numbers confirm what its readers and contributors have long understood: rigorous pharmaceutical science, when curated and disseminated effectively, earns its place at the center of the global research conversation.

Subject of Research: Indexing and citation metrics of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, abstracting and indexing, Clarivate, Web of Science, pharmaceutical sciences, journal metrics, drug development

To understand why indexing in Science Citation Index Expanded carries such weight, it helps to consider what the database actually represents. Maintained by Clarivate, the Science Citation Index Expanded is one of the core components of the Web of Science, the citation ecosystem that underpins the Journal Impact Factor, one of the most scrutinized metrics in academic publishing. Journals are not simply admitted to the index; they must pass through a rigorous evaluation process that examines editorial rigor, publishing timeliness, international diversity among authors and editors, citation behavior, and the overall scholarly contribution of the published work. Inclusion signals to researchers that a journal has met internationally recognized standards of quality and that its articles will be discoverable, citable, and counted in the citation networks that shape modern scientific communication.

The timing of the journal’s admission matters as well. Coverage beginning in 2021 means that articles published from that year onward are tracked in the index, allowing citations to accumulate and, after the standard waiting period, contributing to the Impact Factor calculations released annually. The 2022 Impact Factor of 5.5 reflects the frequency with which articles published in 2020 and 2021 were cited during 2022, normalized across the number of substantive research items the journal published in that window. A value of 5.5 is a strong result in pharmacology, a field where citation patterns are often concentrated in a small number of high-profile journals. Reaching a figure of this magnitude shortly after entering the index is notable, because new entrants typically take several years to build the citation base needed for competitive Impact Factors.

Equally significant is the journal’s position within its category. The Web of Science ranks journals in each subject category both by raw Impact Factor and by percentile, dividing them into quartiles designated Q1 through Q4. Ranking 48th out of 278 journals in Pharmacology and Pharmacy places the Journal of Pharmaceutical Investigation in Q1, the top quartile, roughly the top 17 percent of journals in the category. Many universities, funding agencies, and research assessment exercises treat Q1 status as a benchmark of excellence, and publishing in Q1 journals can influence hiring decisions, grant evaluations, and institutional rankings. For authors weighing where to submit their work, the combination of indexing, a healthy Impact Factor, and Q1 ranking makes the journal a considerably more attractive destination than it was before these achievements.

The mechanics behind these numbers deserve a closer look, because they illuminate how scientific reputation is quantified. The Impact Factor, despite its limitations and the ongoing debate about the role it should play in research assessment, remains the single most requested journal metric worldwide. It is computed by dividing the number of citations in a given year to items published in the journal during the preceding two years by the number of citable items, typically articles and reviews, published in those same two years. Distinguishing between citable and non-citable items, such as editorials, letters, and news pieces, is a frequent source of confusion and contention, but the underlying idea is straightforward: the metric aims to capture the average annual citation rate of a journal’s core scholarly output. A journal that publishes clinically and scientifically relevant work in drug development, formulation, pharmacokinetics, and therapeutic evaluation tends to attract steady citation attention from both academic and industry-affiliated researchers.

For the pharmaceutical research community specifically, the value of robust indexing extends beyond prestige metrics. Pharmaceutics and pharmacology are deeply interdisciplinary fields in which academic laboratories, hospital pharmacists, regulatory scientists, and industrial researchers all draw on the same literature. When a journal is comprehensively indexed in Science Citation Index Expanded, its articles become systematically searchable through Web of Science interfaces and through the many discovery platforms that build on its data. Systematic reviews, meta-analyses, and evidence syntheses, all of which are central to evidence-based pharmacotherapy, depend on comprehensive retrieval of relevant studies. Gaps in indexing can mean that important research is overlooked in these syntheses, so broad coverage benefits not just the journal but the accuracy and completeness of the scientific record as a whole.

The journal’s subject scope explains much of its appeal to contributors and readers. Publications of this kind typically cover investigations spanning drug delivery systems, pharmacokinetics and pharmacodynamics, clinical pharmacy practice, pharmaceutical technology, and therapeutic outcomes, providing a venue for work that bridges laboratory formulation science and clinical application. Research of this type sits at the intersection of chemistry, biology, medicine, and engineering, and its readership spans hospital pharmacies, academic departments of pharmaceutics, regulatory bodies, and pharmaceutical companies. A journal serving such a broad community has a strong incentive to maximize discoverability, since potential authors and readers are distributed across many countries and many professional settings. Indexing in the major citation databases is the most direct route to that visibility, and the Q1 ranking now makes the journal competitive for submissions that might previously have gone to longer-established titles.

It is also worth situating this achievement within broader trends in scholarly publishing. The pharmaceutical sciences have expanded dramatically over the past two decades, driven by biologics, novel drug delivery platforms, nanomedicine, and the growing importance of pharmacoeconomics and health outcomes research. This expansion has multiplied the number of journals competing for high-quality submissions, intensifying pressure on editors to demonstrate quality through metrics. At the same time, the research community and major funders have increasingly questioned overreliance on the Impact Factor, promoting alternatives such as article-level citation measures, preprint visibility, and responsible research assessment frameworks. Even so, indexing status and quartile rankings continue to function as practical gatekeepers in the day-to-day decisions of authors, librarians, and evaluators, which is why a journal’s successful entry into the Science Citation Index Expanded and its attainment of Q1 status remain genuinely newsworthy events for its community.

Looking ahead, the journal’s trajectory will depend on sustaining the editorial standards and citation performance that earned its current standing. Early Impact Factors can be volatile, and consolidating a Q1 position requires consistent publication of work that other researchers find useful and citable. If the journal maintains the quality and breadth that accompanied its 2021 indexing and its 2022 Impact Factor of 5.5, it is well positioned to strengthen its role as a reference point for pharmaceutical investigation internationally. For now, the combination of Science Citation Index Expanded coverage, a solid Impact Factor, and a top-quartile category ranking represents a clear vote of confidence from the bibliometric infrastructure that helps determine which journals the global research community reads, cites, and trusts.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Web of Science, Impact Factor, Q1 journal, Pharmacology and Pharmacy, journal indexing, citation metrics, pharmaceutical sciences, Clarivate, scholarly publishing

The Science Citation Index Expanded, often encountered by researchers under its search interface name SciSearch or through the Web of Science platform, functions as a comprehensive record of scholarly articles across the natural sciences, engineering, and medicine. When a journal is accepted into the index, every published article receives structured metadata — authors, affiliations, abstracts, keywords, and references — that allows the paper to be retrieved, linked, and counted. Citations flowing between indexed journals form the raw material for a family of quantitative indicators, most famously the Journal Impact Factor, that have become embedded in hiring, funding, and institutional evaluation processes around the world. Absence from the index, by contrast, can leave even high-quality research effectively invisible to large portions of the international community, particularly automated literature-discovery systems and systematic review workflows that rely on indexed databases as their primary search universe.

Following its inclusion, the Journal of Pharmaceutical Investigation recorded a Journal Impact Factor of 5.5 for 2022, a figure derived from the ratio of citations received in that year to the citable items — typically original research articles and reviews — published during the preceding two-year window. In the subject category of Pharmacology and Pharmacy, that score corresponded to a ranking of 48th out of 278 indexed journals, placing the publication in the first quartile, or Q1, of its field. Quartile position is a compressed but influential signal: it indicates that a journal sits among the top quarter of titles in its discipline by citation density, and many institutions explicitly require Q1 placement when researchers select venues for their work. For a journal that had operated for years outside the indexed core, the debut performance represents an unusually strong entry.

The mechanics behind these numbers are worth unpacking, because they explain both the value and the limitations of the metric. An impact factor of 5.5 means that, on average, each citable item published by the journal in 2020 and 2021 was cited 5.5 times in 2022 across the entire indexed literature. Review articles, which synthesize large bodies of work and are cited heavily, can inflate this average; so can a small number of highly cited papers in a small publication volume. Journal size, publication frequency, and topical timing all introduce volatility, which is why bibliometric experts consistently caution against treating the impact factor as a direct measure of the quality of any individual paper. A citation to a specific article is a vote for that article’s usefulness, not for every article sharing the same masthead. Nevertheless, at the level of journal selection — deciding where to submit, which subscriptions to fund, or which titles to trust for rapid scanning — the metric retains enormous practical weight, and a Q1 ranking in a competitive category such as Pharmacology and Pharmacy, where 278 titles compete, signals genuine traction with the research community.

The context in which this achievement occurred matters as much as the number itself. Pharmaceutical investigation as a discipline sits at a crowded crossroads: medicinal chemistry, pharmacokinetics, drug delivery, clinical pharmacology, and regulatory science all generate vast literatures, and hundreds of journals compete for the manuscripts that result. In such an environment, visibility is a scarce resource. Authors increasingly consult journal metrics before submitting, and funding agencies in many countries now ask applicants to characterize the venues in which their prior work appeared. A journal’s entry into the Science Citation Index Expanded therefore changes its competitive position in a feedback loop that can accelerate over successive years: indexing brings discoverability, discoverability brings readers and citations, citations bring higher metrics, and higher metrics attract stronger submissions, which in turn reinforce the citation profile. Editorial teams are well aware of this dynamic, which is why indexing milestones are often described within the publishing industry as inflection points rather than endpoints.

For the research community in pharmaceutical science, the practical consequences of indexing are concrete. A scientist in Seoul, São Paulo, or Stockholm running a structured literature search through Web of Science will now surface relevant articles from the journal that previously would have been missed by that particular query, even if they were retrievable through other services such as PubMed or Scopus. Systematic reviewers, who follow strict protocols requiring multi-database searching to avoid bias, can now legitimately include the journal in their source lists. Bibliometric analysts mapping collaboration networks or tracking research fronts in drug development will find its citation links woven into their datasets. Even citation managers and reference-checking tools benefit, because indexed metadata is typically cleaner and more complete than the free-text records scraped from journal websites. In short, indexing converts a journal from an isolated island of content into a node in the interconnected graph of global scholarship.

The milestone also reflects broader changes in how scholarly publishing evaluates and rewards journals. The Science Citation Index Expanded has tightened its acceptance criteria over the past decade, applying a consistent editorial standards review that examines publication ethics, peer-review rigor, editorial board composition, timeliness, and international authorship alongside raw citation performance. Journals are no longer admitted simply because they publish frequently; they must demonstrate sustainable editorial governance and adherence to the community’s ethical norms. Achieving inclusion in the 2021 cycle therefore implies that the journal passed a substantive vetting process covering both its operational practices and the scientific standing of its published content. This dual scrutiny is one reason why indexing status carries credibility with institutions that must make funding and promotion decisions without reading every paper themselves.

At the same time, the pharmaceutical sciences are undergoing a transformation that gives journals in this field unusual strategic importance. The past several years have seen unprecedented attention to drug development — from the rapid clinical evaluation of vaccines and antivirals to the rise of biologics, mRNA platforms, and precision medicine approaches tailored to molecular subtypes of disease. Each of these frontiers generates intense publication activity, and the citation metrics of journals in Pharmacology and Pharmacy have shifted accordingly, with the field’s leading titles posting some of the strongest citation growth in the biomedical sciences. A journal entering the indexed landscape during such a period inherits both opportunity and pressure: the appetite for pharmaceutical research findings is enormous, but so is the competition, and new entrants must quickly establish editorial identity — whether in translational pharmacology, formulation science, or clinical investigation — to convert visibility into durable citation performance.

Looking ahead, the trajectory of the journal will depend on factors that no single metric can fully capture. Sustaining a Q1 position requires consistent editorial output, successful attraction of high-impact submissions, and continued adherence to the standards that secured indexing in the first place. Citation databases conduct periodic re-evaluation, and titles that slip in quality or timeliness can be discontinued from coverage, a risk that keeps editorial offices accountable long after the initial acceptance. For now, however, the combination of Science Citation Index Expanded coverage and a first-quartile impact factor of 5.5 gives the Journal of Pharmaceutical Investigation the visibility infrastructure and quantitative credentials that authors, reviewers, and readers in the global pharmaceutical research community rely upon when deciding where the most consequential work in their field is being published and debated.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Journal Impact Factor, pharmacology and pharmacy, Q1 journal ranking, abstracting and indexing, Web of Science, bibliometrics, scholarly publishing, pharmaceutical sciences, citation metrics, Clarivate Analytics

Abstracting and indexing is the process by which a bibliographic database systematically catalogs a journal’s articles, capturing standardized metadata such as titles, authors, affiliations, abstracts, keywords and references, and making that metadata searchable across a global platform. The practical consequence for researchers is discoverability. An article that appears only on an individual journal website exists in a kind of bibliographic isolation, reachable mainly by readers who already know the journal. Once a journal is indexed in the Science Citation Index Expanded, its content becomes discoverable through Web of Science search tools, its citation links become traceable through the database’s cited-reference searching, and its cumulative performance becomes visible to the librarians, funders and evaluation committees who rely on these databases when they assess journals and institutions. In an era when most literature discovery begins with a database query rather than a browse of a journal’s table of contents, indexing status is a structural determinant of a paper’s audience.

The Science Citation Index Expanded is the multidisciplinary extension of the original Science Citation Index, the citation database created by Eugene Garfield in the 1960s and now maintained as part of the Web of Science Core Collection. The index covers thousands of journals across the natural sciences, applied sciences and medicine, and its selection process is deliberately selective. Editors evaluating a journal for inclusion consider a range of quality signals: the rigor and consistency of peer review, the international diversity of the editorial board and authorship, the regularity of publication, the ethical publishing standards in place, and the citation behavior of the journal’s published content. Journals are re-evaluated continuously, and inclusion is not permanent, which means that a journal’s presence in the index is itself an ongoing signal that its editorial standards continue to meet the database’s criteria.

The impact factor reported alongside the indexing record is the metric most closely watched by authors deciding where to submit their work. Calculated annually by Clarivate from the citation data in the Web of Science, the two-year impact factor for a given year is the ratio of citations received in that year to the number of substantive items, typically articles and reviews, published in the journal during the two preceding years. A 2022 impact factor of 5.5 therefore reflects citations accumulated in 2022 by papers published in 2020 and 2021, divided by the count of those papers. For a journal that entered the index in 2021, this figure arrives early in its indexed life, since new journals typically need a settling period before their citation patterns stabilize. The value of 5.5 indicates that, on average, each citable item published in the journal during the measurement window drew more than five citations in the following year, a level of citation intensity that corresponds to a strong, internationally visible research venue in the pharmaceutical field.

Quartile placement translates that raw number into context. Journals in a Web of Science category are ranked by impact factor and divided into four groups, with the first quartile, Q1, containing the top 25 percent. The Journal of Pharmaceutical Investigation’s position at 48 out of 278 journals in Pharmacology and Pharmacy places it firmly within that top band, ahead of roughly four-fifths of the journals in its category. The rank matters because impact factors are meaningful only in comparison. A value of 5.5 might be modest in a field with extremely high citation rates and exceptional in a field where citation density is low; the quartile ranking situates the journal relative to the actual distribution of its peers in pharmacology and pharmacy. Authors evaluating potential outlets, and readers skimming reference lists for authoritative sources, use these rankings as a fast heuristic for gauging where a journal stands within its discipline.

The downstream effects of this status are practical for the research community. Authors gain a publication venue whose indexed metrics can be cited in grant applications, promotion dossiers and funder reports, where journal quality is often assessed through Web of Science-based indicators. Institutions benefit because their researchers’ publications contribute to institutional citation profiles and to the global university rankings that draw heavily on Web of Science data. Readers benefit from the cited-reference network that the index builds, allowing them to trace the lineage of a finding backward through earlier work and forward through later citations. Librarians use the indexing record and the impact factor when making subscription decisions, which in turn supports the journal’s financial sustainability. In this way, a single indexing milestone ripples outward through nearly every stakeholder in the scientific communication system.

The pharmaceutical sciences present a particularly demanding environment for journal metrics. The field spans drug discovery, formulation science, pharmacokinetics, drug delivery systems, clinical pharmacology and regulatory science, and its publication landscape is crowded with long-established titles backed by major societies and commercial publishers. Citation behavior in the field is shaped by translational urgency: work on delivery platforms, biologics and therapeutic development often draws attention from both basic researchers and clinical communities, which can drive citation counts upward for journals positioned at those intersections. A journal focused on pharmaceutical investigation sits naturally in that translational zone, and the first-quartile ranking suggests that its published research is being picked up across both the pharmaceutical technology and the pharmacology communities that make up its readership.

At the same time, the announcement is a fitting occasion to recall the limits of the metrics involved. The research community has increasingly emphasized responsible use of quantitative indicators. The San Francisco Declaration on Research Assessment, signed by thousands of journals, funders and institutions, urges that impact factors not be used as a surrogate for the quality of individual papers or the merit of individual researchers, since citation counts are influenced by article type, review articles inflate averages, and two-year windows capture only a slice of a paper’s scholarly lifetime. Altitude within a quartile shifts year to year as citation patterns fluctuate, and a journal’s impact factor is a property of the journal, not a guarantee about any single article it publishes. The appropriate reading of the 2022 record is therefore as a signal of the journal’s overall standing and editorial health, not as a per-article quality certificate.

For the broader community of pharmaceutical researchers, the development adds one more indexed, first-quartile outlet to a field where the demand for visible, credible publication venues remains intense. Inclusion in the Science Citation Index Expanded from 2021 onward means that the journal’s recent volumes are being woven into the global citation fabric that underlies literature search, systematic review, bibliometric analysis and research evaluation. Its 2022 impact factor of 5.5 and its Q1 position at 48 of 278 journals in Pharmacology and Pharmacy provide a quantified snapshot of that integration. Whether the journal sustains and improves those numbers will depend on the same fundamentals that determine any journal’s trajectory: the quality and relevance of the research it attracts, the rigor of its peer review, and its continued adherence to the editorial standards that earned it entry into one of scholarly publishing’s most closely watched databases.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor of 5.5 in pharmacology and pharmacy.

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, impact factor, Journal of Pharmaceutical Investigation, pharmacology, pharmacy, Web of Science, quartile ranking, scholarly publishing, pharmaceutical sciences, journal metrics, research visibility

Abstracting and indexing is the process by which a journal’s published articles are systematically catalogued in major bibliographic databases, allowing them to be discovered, cited, and tracked by the global research community. Inclusion in the Science Citation Index Expanded, one of the core citation databases maintained within the Web of Science platform, signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial board composition, peer-review integrity, international diversity of authorship, and the consistency of its scholarly output. For pharmaceutical researchers, this means that articles appearing in the journal are now fully searchable alongside the most influential literature in pharmacology and pharmacy, and that citations to those articles are counted in official journal metrics.

The Impact Factor, the most widely recognized of these metrics, is calculated by dividing the number of citations received in a given year by articles published in the two preceding years. A value of 5.5 for 2022 indicates that, on average, papers published in the journal during 2020 and 2021 were cited 5.5 times in 2022. This figure places the journal comfortably within the upper tier of its category, since quartile rankings divide the journals in a subject class into four equal groups by citation performance. A Q1 designation, corresponding to the top 25 percent of the 278 journals ranked in Pharmacology and Pharmacy, is a benchmark many institutions use when assessing publication quality for hiring, promotion, and funding decisions.

The rank of 48 out of 278 is particularly notable in a category as large and competitive as Pharmacology and Pharmacy, which spans everything from basic molecular pharmacology to clinical therapeutics and pharmaceutical manufacturing. Journals in this category compete for citations from a vast body of global research, and moving into the first quartile typically requires sustained growth in both the quality and the visibility of published work. For a journal focused specifically on pharmaceutical investigation, the achievement reflects the growing citation footprint of research on drug delivery systems, nanomedicine, pharmacokinetics, and the formulation technologies that translate laboratory discoveries into clinical products.

Indexing in SciSearch since 2021 means the journal’s metrics are still relatively young within the Web of Science ecosystem, which makes the 2022 Impact Factor an early but meaningful indicator of its trajectory. New journals often take several years to accumulate the citation history needed for stable rankings, and early Impact Factors can fluctuate as the indexed back-file grows. A first-quartile placement within roughly two years of indexing suggests that the journal’s existing body of work was already attracting substantial citations, and that its inclusion in the database made that influence visible to the evaluators, librarians, and researchers who rely on these metrics to navigate the literature.

The practical consequences of indexing and quartile performance extend well beyond prestige. Researchers choosing where to submit manuscripts frequently consult journal rankings to maximize the reach and career value of their work, and many funding agencies and universities maintain lists of approved outlets based on Web of Science categories and quartiles. Librarians use the same data to make subscription decisions. For authors in pharmaceutical sciences, a Q1 journal with a 5.5 Impact Factor offers a combination of disciplinary focus and broad discoverability that can accelerate the uptake of new methods, from controlled-release formulations to novel excipients and biopharmaceutical characterization techniques.

Bibliometric experts caution, however, that the Impact Factor is a blunt instrument. It measures average citations to a two-year window of articles and can be influenced by a small number of highly cited reviews, by the overall volume of publication, and by citation practices that vary across subfields. Pharmacology and pharmacy journals, which sit at the interface of basic science and applied medicine, often benefit from citation patterns that differ from those of purely clinical or purely basic titles. For this reason, evaluators are increasingly encouraged to read quartile rankings alongside other indicators, such as the journal’s scope, its peer-review standards, and the actual readership of individual papers rather than journal-level averages alone.

Even with those caveats, the formal recognition matters for the research community the journal serves. Pharmaceutical investigation is a field in which translational timelines are long and the path from molecular discovery to approved therapy depends on shared methodological standards. When a specialized journal achieves first-quartile status, it strengthens the visibility of the applied and formulation-oriented research that often falls between the traditional categories of pharmacology and chemical engineering. This can help ensure that advances in drug delivery technology, bioequivalence assessment, and pharmaceutical quality control receive the same citation attention as breakthroughs in target discovery or clinical trial results.

The journal’s listing with Springer, which publishes the title as part of its pharmaceutical sciences portfolio, provides the authoritative record of its indexing status and metric performance. The publisher’s announcement confirms both the 2021 start of Science Citation Index Expanded coverage and the 2022 Impact Factor of 5.5, along with the category rank of 48 out of 278 in Pharmacology and Pharmacy. These figures will be updated annually as new citation data become available, and the journal’s position will be watched by authors, editors, and bibliometric analysts alike as an indicator of how specialized pharmaceutical research titles fare in an increasingly metrics-driven publishing environment.

For the broader scientific publishing landscape, the case illustrates how abstracting and indexing functions as the gateway through which journals enter the formal economy of scholarly recognition. Without inclusion in the major citation databases, even high-quality research risks invisibility in the evaluations that shape careers and funding. With inclusion, and with a strong early Impact Factor, a journal can rapidly become a destination for the work that defines its field. The Journal of Pharmaceutical Investigation’s Q1 standing demonstrates that a focused pharmaceutical title can achieve that recognition quickly, provided its published research resonates with the citation behavior of the international pharmacology and pharmacy community.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 rank of 48/278 in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, quartile ranking, pharmacology and pharmacy, Web of Science, bibliometrics, pharmaceutical sciences, Springer, citation metrics

Abstracting and indexing services form the backbone of scientific communication infrastructure. When a journal is abstracted and indexed, its article records, including titles, author names, affiliations, abstracts and bibliographies, are systematically captured and catalogued in large bibliographic databases that researchers around the world use every day. Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and widely consulted of these services. Inclusion signals that a journal has passed editorial quality assessments covering peer-review rigor, publication ethics, editorial board composition, timeliness and international reach. For a pharmaceutical sciences journal, this recognition is particularly consequential because the field spans chemistry, pharmacology, formulation science, clinical investigation and regulatory science, and its researchers rely on comprehensive literature discovery to avoid duplication and build on prior findings.

The mechanics of indexing are less visible to readers but essential to how science circulates. Once a journal is accepted into SciSearch, every published article receives consistent metadata treatment: digital object identifiers are registered, citations between articles are tracked, and bibliometric algorithms can count how often a paper is referenced by later work. This citation network is what makes quantitative measures possible in the first place. Without structured indexing, citation counts would be fragmented across publisher websites and impossible to aggregate reliably. Indexed status also enables discovery through search platforms that institutions license, meaning a clinical pharmacist in Seoul or a formulation scientist in Boston encounters the journal’s content through the same trusted databases rather than through scattered web searches.

The impact factor of 5.5 reported for 2022 is calculated through a well-defined formula: it counts the citations received in that year by articles the journal published in the two preceding years, divided by the number of citable items, typically research articles and reviews, published in those same two years. A value of 5.5 means that, on average, recent articles in the journal were cited more than five times within roughly two years of publication, a strong performance in pharmacology and pharmacy, where citation patterns tend to be steadier and more gradual than in fast-moving fields such as molecular biology. The Q1 designation, derived from the journal’s position at 48 of 278 in its category, means it falls within the top quartile of titles, a threshold many institutions use as a benchmark for high-quality publication.

Within the pharmaceutical research community, these metrics carry practical weight. Journals that rank highly attract manuscripts from established laboratories, which in turn raises the technical quality and relevance of published work, creating a feedback loop of visibility and citation. For authors, publishing in an indexed, Q1-ranked journal ensures that their findings are counted in institutional assessments, grant applications and national research evaluation frameworks, many of which explicitly require Web of Science or Scopus inclusion. For readers, the ranking acts as a quality heuristic, a signal that the peer review process has historically filtered submissions with reasonable strictness. For librarians managing tight budgets, category rank and impact factor often inform subscription and renewal decisions, so a journal’s bibliometric performance directly shapes whether researchers can access it at all.

The journal’s subject area itself explains why this recognition resonates. Pharmaceutical investigation encompasses preclinical drug evaluation, pharmacokinetics and pharmacodynamics, novel delivery systems, nanotechnology-based formulations, biopharmaceutics and translational research linking laboratory findings to clinical outcomes. This is a domain where the pace of innovation is accelerating, driven by biologics, RNA therapeutics, targeted delivery platforms and computational drug design. Researchers in these areas depend on rapid, reliable access to peer-reviewed results, and a journal embedded in the core citation indexes effectively becomes part of the discipline’s shared memory. Articles that might otherwise remain niche become discoverable through citation chains, review articles and database alerts.

Entry into Science Citation Index Expanded in 2021 marked a milestone because that year is the starting point from which the journal’s citation record accumulates in the index. Impact factors for newly indexed journals require a lag period before the citation window contains sufficient data, so the 5.5 figure for 2022 represents the first full measurement of the journal’s citation performance within the service. Achieving a Q1 rank in that early measurement window is notable, since it indicates that work published in the journal was already being cited at a level competitive with long-established titles in pharmacology and pharmacy. It also suggests that the journal’s editorial scope aligns with active research fronts where citation activity is naturally concentrated.

Bibliometric indicators should nevertheless be read with nuance, a point widely acknowledged across the scholarly communication community. An impact factor describes the average citation behavior of a journal’s recent output, not the quality of any individual article, and citation counts vary by article type, topic popularity and review share. A journal publishing influential methodological reviews may see its average lifted relative to one focused on narrow empirical studies. Category rankings are more robust because they compare journals within the same discipline, but they still aggregate across subfields with different citation customs. Researchers and evaluators are therefore encouraged to treat the 5.5 impact factor and Q1 rank as one signal among several, alongside peer review reports, replication records and the actual content of the research itself.

For the journal’s editorial team, sustained indexing brings ongoing obligations. Indexed journals must maintain consistent publication schedules, transparent peer review workflows, correctable article records and adherence to publishing ethics standards. Data integrity, authorship transparency and conflict-of-interest disclosure are scrutinized both at submission and in periodic re-evaluation by indexing services, which can delist journals that fall short. This accountability framework benefits the entire pharmaceutical sciences community: it keeps the citation record trustworthy, ensures that meta-analyses and systematic reviews rest on verifiable sources, and protects early-career researchers who stake their careers on publications whose provenance must withstand institutional scrutiny.

As pharmaceutical research grows more interdisciplinary, the role of well-indexed journals as connective tissue between chemistry, biology, engineering and clinical medicine will only expand. The Journal of Pharmaceutical Investigation’s presence in Science Citation Index Expanded since 2021, combined with its 2022 impact factor of 5.5 and its Q1 standing at 48 of 278 in Pharmacology and Pharmacy, positions it as a reference point for researchers navigating this crowded landscape. Whether these metrics translate into durable scientific influence depends on the quality of the work the journal continues to publish and the rigor of its editorial processes, but the early indicators suggest that its articles are reaching the audiences positioned to build on them, cite them and, ultimately, convert them into better medicines.

Subject of Research: Abstracting, indexing and citation performance of the Journal of Pharmaceutical Investigation in Web of Science and pharmacology journal rankings

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Web of Science, impact factor, Q1 journal, Pharmacology and Pharmacy, pharmaceutical sciences, bibliometrics, scholarly publishing, citation metrics

Abstracting and indexing, often abbreviated as A&I, is the process by which bibliographic databases catalog scholarly articles, capturing their titles, authors, abstracts, keywords and citations in structured records that can be searched, sorted and analyzed at scale. For researchers, these databases are the primary discovery tools of modern science: a paper that is not indexed in the major services is effectively invisible to most of the global research community, no matter how rigorous its methods or how significant its findings. For journals, inclusion in prestigious indexes is both a badge of quality and a practical necessity, because libraries, funders and tenure committees routinely evaluate publications based on where they are indexed and what citation metrics those indexes generate.

The Journal of Pharmaceutical Investigation has been abstracted and indexed in the Science Citation Index Expanded, commonly known as SciSearch, since 2021. The Science Citation Index Expanded is maintained by Clarivate as part of the Web of Science platform, one of the most authoritative citation databases in the world. It traces its lineage to the original Science Citation Index created by Eugene Garfield in the 1960s, a pioneering effort to map the flow of ideas through the scientific literature by tracking which papers cite which. That citation network remains the foundation of modern bibliometrics, and inclusion in the expanded index signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial content, international diversity and citation behavior.

Once a journal is indexed in the Science Citation Index Expanded, it becomes eligible for the Journal Impact Factor, the single most widely cited metric in scholarly publishing. The impact factor is calculated by dividing the number of citations received in a given year by items published in the journal during the two preceding years. A journal’s 2022 impact factor of 5.5 therefore means that, on average, articles published in 2020 and 2021 were cited 5.5 times each during 2022. While the metric has well-documented limitations, it remains a shorthand that researchers, institutions and publishers watch closely, and movement in the rankings can shape manuscript submission patterns, editorial strategies and even national research assessment frameworks.

A ranking of 48 out of 278 journals places the Journal of Pharmaceutical Investigation in the first quartile, or Q1, of the Pharmacology and Pharmacy category, meaning it sits among the top 25 percent of titles in its field. Quartile rankings are derived by ordering journals within a category by impact factor and dividing them into four equal bands. Q1 status is particularly meaningful in pharmacology, one of the most competitive categories in the Web of Science, where established titles with decades of history and enormous submission volumes compete for citation attention. For a journal to reach and hold a Q1 position, its published work must not only meet high editorial standards but also resonate with a broad community of researchers who choose to cite it in their own studies.

The journal’s subject matter helps explain that resonance. Pharmaceutical investigation encompasses the entire lifecycle of a drug, from early discovery and formulation science through pharmacokinetics, pharmacodynamics, clinical evaluation, manufacturing quality and post-marketing surveillance. Research in this space is inherently translational, connecting laboratory findings to therapeutic outcomes, and it draws citations from a wide range of adjacent disciplines, including biotechnology, nanomedicine, regulatory affairs and clinical pharmacy. Journals that publish work spanning this breadth tend to accumulate citations from many communities, which strengthens their bibliometric performance and, in a self-reinforcing loop, attracts further high-quality submissions from authors seeking visibility.

The timing of the journal’s SciSearch inclusion in 2021 and its subsequent impact factor performance illustrates a broader dynamic in scholarly publishing. New or newly indexed journals typically need two full publication cycles before their first official impact factor can be calculated, because the metric depends on a two-year citation window. The years immediately following indexing are therefore critical: editors work to commission review articles, which are disproportionately cited, and to attract original research from prominent groups, knowing that early citation performance will set the trajectory of the journal’s metrics for years to come. Achieving a 5.5 impact factor within a short period of entering the index suggests that the journal’s editorial strategy and its community of contributors have aligned effectively with the citation patterns of contemporary pharmaceutical research.

Behind the headline numbers lies an elaborate ecosystem of data infrastructure. When an article is published, its metadata are transmitted to indexing services, where they are normalized against standards for author names, affiliations, funding information and references. Citation links are then resolved and aggregated, feeding not only the impact factor but also a family of related indicators, including the five-year impact factor, the immediacy index, the cited half-life and the eigenfactor, each of which captures a different dimension of a journal’s scholarly footprint. Databases also power literature search engines, reference managers and systematic review workflows, meaning that indexing quality directly affects how efficiently science itself proceeds. Errors or gaps in indexing can delay discoveries, skew bibliometric analyses and misrepresent the provenance of ideas.

For the pharmaceutical sciences specifically, robust indexing carries practical stakes beyond prestige. Systematic reviews and meta-analyses, which underpin clinical guidelines and regulatory decisions, depend on comprehensive database coverage to identify all relevant evidence. Pharmacovigilance researchers tracking adverse events, formulation scientists surveying delivery technologies and health economists assessing drug value all rely on indexed literature to build complete pictures of the evidence base. A journal’s presence in the Science Citation Index Expanded therefore contributes to the reliability of the evidence synthesis on which drug safety and efficacy decisions ultimately rest, a responsibility that extends well beyond the publishing world into patient care.

The Journal of Pharmaceutical Investigation’s Q1 standing in 2022 is a snapshot of a competitive and rapidly evolving field, and maintaining that position will require continued editorial rigor as publishing itself changes. Preprint servers, open access mandates, alternative metrics and new assessment frameworks such as the Declaration on Research Assessment are reshaping how scholarly value is measured, and citation-based indicators are increasingly scrutinized for the ways they can be gamed or misapplied. Yet for now, the combination of SciSearch indexing and a 5.5 impact factor confirms the journal’s place among the leading venues for pharmaceutical research, offering authors a platform with global discoverability and offering readers a curated window into the science that moves molecules from the bench to the bedside.

Subject of Research: The indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor and Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, abstracting and indexing, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, pharmaceutical sciences, bibliometrics, Clarivate

Abstracting and indexing is the infrastructure that underpins the modern scientific record. When a journal is accepted into a major citation index, its articles become discoverable through the databases that scientists, clinicians, and institutions rely on every day to survey the literature. The Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and influential of these databases. Inclusion signals that a journal has passed rigorous editorial evaluation covering publishing standards, peer-review integrity, international editorial breadth, and citation behavior. For a journal to be abstracted and indexed in SciSearch from 2021 onward means that every article it publishes is now woven into the global web of citation data that powers literature searches, systematic reviews, bibliometric analyses, and institutional assessments.

The consequences of that inclusion ripple outward quickly. A paper on a novel nanoparticle formulation or a new approach to oral drug absorption that might once have been seen primarily by the journal’s existing readership can now surface in the reference lists, alerts, and search results of researchers on every continent. Citations accumulate, and those citations feed directly into the journal’s Impact Factor, the most scrutinized single number in scholarly publishing. The 2022 Impact Factor of 5.5 for the Journal of Pharmaceutical Investigation reflects the average number of times articles published in the preceding two years were cited during 2022. Crossing the threshold into double-digit percentile territory in a crowded category is a meaningful achievement that reflects both the quality of the work the journal publishes and the engagement of the community that reads it.

The ranking attached to that Impact Factor deserves particular attention. The Journal of Pharmaceutical Investigation’s position of 48 out of 278 journals in the Pharmacology and Pharmacy category places it in the Q1 band, the top quartile of its discipline. Quartile rankings divide a category’s journals into four groups by citation performance, and Q1 status is frequently used by funding agencies, hiring committees, and universities as shorthand for excellence. In a field as broad and competitive as pharmacology and pharmacy, which spans everything from medicinal chemistry and pharmacokinetics to clinical pharmacy practice and health economics, occupying the top quartile requires a journal to be cited at rates that exceed roughly three-quarters of its peers. That is a demanding standard in a category where established, decades-old titles compete for the same citations.

Understanding why these metrics matter requires a look at how scientific visibility actually works. Researchers cannot read everything; the volume of pharmaceutical literature published each year runs to hundreds of thousands of articles. Search engines, recommendation tools, and citation databases act as filters, and journals that are indexed in the major databases are dramatically more likely to appear in those filters. An article that is not indexed is, for practical purposes, invisible to much of the global research community, no matter how rigorous its methods or how important its findings. Indexing in SciSearch therefore functions as a guarantee of discoverability, ensuring that the pharmaceutical research published in the journal can be found by the translational scientists, formulation chemists, regulatory affairs professionals, and clinicians who might build on it.

For authors, the practical implications are considerable. Early-career scientists choosing where to submit their work weigh the visibility of a journal heavily, because citations shape careers: grant applications, promotions, and tenure decisions all lean on publication records. A journal with a 5.5 Impact Factor and a Q1 ranking offers a persuasive combination of reach and prestige, particularly for interdisciplinary work in drug delivery, pharmacokinetics, and pharmaceutical technology where the readership spans pharmacy, chemistry, materials science, and medicine. Authors also gain the assurance that their work will be captured in institutional repositories, reported in faculty citation profiles, and counted in national research assessments that draw on Web of Science data.

For readers and research institutions, indexing and citation metrics serve a different but equally important function: they act as quality signals in an environment of information overload. Libraries use indexing status and citation performance to make subscription decisions, allocating finite budgets toward journals that their communities actually use and cite. Systematic reviewers and meta-analysts, whose syntheses of the literature inform clinical guidelines and regulatory decisions, depend on indexed databases to ensure their searches are comprehensive. When a journal is reliably indexed, reviewers can trust that its content will be captured in their search strategies, reducing the risk that important evidence is overlooked. In pharmaceutical research, where a missed finding can influence drug development decisions with billions of dollars and patient safety at stake, that reliability carries real weight.

The journal’s trajectory also illustrates broader dynamics in scholarly publishing. Impact Factors are recalculated annually and can shift with changes in a field’s citation culture, the timing of highly cited articles, and the growth of a journal’s readership. A journal that earns a strong Impact Factor often enters a virtuous cycle: greater visibility attracts stronger submissions, stronger submissions attract more citations, and more citations reinforce the metrics that drew authors in the first place. Entering the Science Citation Index Expanded in 2021 gave the Journal of Pharmaceutical Investigation access to exactly this cycle, and the 2022 figure of 5.5 provides early evidence that the cycle is turning favorably. Sustaining that position will depend on continued editorial rigor, timely publication, and the ability to anticipate where pharmaceutical science is heading next.

Pharmaceutical investigation itself is a field in the midst of remarkable ferment, and the research indexed under this journal’s banner reflects that energy. Drug delivery science is being reshaped by lipid nanoparticles, antibody-drug conjugates, and mRNA platforms whose importance the pandemic made unmistakable. Pharmacokinetic modeling increasingly incorporates artificial intelligence and physiologically based simulation to predict human outcomes from preclinical data. Formulation scientists are tackling biologics, cell therapies, and nucleic acid medicines that defy the traditional tools of the discipline. A Q1-ranked journal embedded in this landscape functions as a convergence point, drawing together the pharmacists, chemical engineers, clinicians, and data scientists whose combined work determines whether laboratory discoveries become medicines on pharmacy shelves.

As the Journal of Pharmaceutical Investigation continues its indexed run, its citation record will be watched not only by its editors and authors but by the wider community that relies on bibliometric indicators to navigate an expanding literature. The 2022 Impact Factor of 5.5 and the Q1 rank of 48 out of 278 in Pharmacology and Pharmacy establish a clear benchmark, and they assure researchers that work published in the journal will be counted, cited, and seen. In a scientific ecosystem where discoverability can determine whether a finding shapes a new therapy or fades unread, the combination of rigorous peer review, inclusion in the Science Citation Index Expanded, and strong citation performance represents the difference between publishing and truly communicating. For pharmaceutical science, one of the most consequential research endeavors of the age, that distinction matters.

Subject of Research: Abstracting, indexing, and citation performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, Science Citation Index Expanded, SciSearch, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, drug delivery, scholarly publishing, pharmaceutical sciences

To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal